Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 4/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | FPR3 | P25089 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15054715 | 0.88 | RORC (0.51) | RORCNR1H2NR1H3TACR1 | |
| SCHEMBL25075376 | 0.88 | RORC (0.51) | RORCNR1H2NR1H3TACR1 | |
| SCHEMBL31703732 | 0.88 | RORC (0.51) | RORCNR1H2NR1H3TACR1 | |
| SCHEMBL28959865 | 0.83 | RORC (0.46) | RORCNR1H2NR1H3TACR1HSD11B1 | |
| SCHEMBL29481460 | 0.81 | TACR1 (0.43) | RORCNR1H2NR1H3TACR1USP30 | |
| SCHEMBL23013151 | 0.81 | TACR1 (0.43) | RORCNR1H2NR1H3TACR1USP30 | |
| SCHEMBL7890064 | 0.78 | PDE4B (0.58) | RORCTACR1USP30PDE4BFPR2 | |
| SCHEMBL15156078 | 0.77 | RORC (0.49) | RORCNR1H2NR1H3HSD11B1USP30 | |
| SCHEMBL20148981 | 0.77 | RORC (0.68) | RORCNR1H2NR1H3TACR1USP30 | |
| SCHEMBL20139618 | 0.77 | RORC (0.68) | RORCNR1H2NR1H3TACR1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083722-A1 | BIFUNCTIONAL DEGRADERS COMPRISING ELECTROPHILIC PROTACS THAT ENGAGE DCAF1 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SCRIPPS RESEARCH INST (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250034216-A1 | STEREOSELECTIVE COVALENT LIGANDS FOR ONCOGENIC AND IMMUNOLOGICAL PROTEINS | THE SCRIPPS RESEARCH INSTITUTE | 2025-01-30 | — | — | US | disclosed |
| WO-2023225625-A2 | BIFUNCTIONAL DEGRADERS COMPRISING ELECTROPHILIC PROTACS THAT ENGAGE DCAF1 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023092133-A1 | STEREOSELECTIVE COVALENT LIGANDS FOR ONCOGENIC AND IMMUNOLOGICAL PROTEINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083722-A1 | BIFUNCTIONAL DEGRADERS COMPRISING ELECTROPHILIC PROTACS THAT ENGAGE DCAF1 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | DCAF1, MDM2, ADRM1 | RORC 2085/4885NR1H2 3545/4885NR1H3 4047/4885 |
| US-20250034216-A1 | STEREOSELECTIVE COVALENT LIGANDS FOR ONCOGENIC AND IMMUNOLOGICAL PROTEINS | CD2BP2, TP53, CD74 | RORC 657/4885NR1H2 2960/4885NR1H3 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.